ArticleScientific reports2026
Allophycocyanin inhibits HIV-1 gp120 and reverse transcriptase through enthalpy-driven binding and antioxidative protection: integrative computational and experimental insights.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin BRSC advances · 2026Article
- Antiviral Potential of Green-Synthesized Zinc Oxide and Copper Oxide Nanoparticles: Integrated In Vitro and In Silico Study.Nanomaterials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge, underscoring the need for antiviral strategies that extend beyond conventional small-molecule inhibitors. Here, we investigate the cyanobacterial phycobiliprotein allophycocyanin (APC) as a natural macromolecular scaffold with combined antiviral and antioxidant activities. Integrative protein-protein docking and long-timescale molecular dynamics simulations revealed stable APC interactions with HIV-1 gp120, protease, and reverse transcriptase (RT), with gp120 displaying the most favorable binding propensity based on qualitative free-energy ranking and interfacial stability. Isothermal titration calorimetry demonstrated a moderate, enthalpy-driven gp120-APC interaction in solution, consistent with a transient yet biologically relevant protein-protein association. In HIV-1-infected cells, APC treatment reduced viral protein abundance, including gp120, protease, and RT, and significantly inhibited RT enzymatic activity. APC also mitigated infection-induced oxidative stress, restoring redox balance toward basal levels. While computational affinity estimates are semi-quantitative and cellular uptake mechanisms were not directly examined, the combined structural, biophysical, and cellular data support a model in which APC interferes with viral entry and downstream replication while providing host-protective antioxidant effects. Collectively, this study advances APC from a general antioxidant biomolecule to a mechanistically characterized natural macromolecular inhibitor with potential relevance as an adjunctive anti-HIV-1 strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.